Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- About
AVDL 
Avadel Pharmaceuticals PLC (AVDL)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
02/11/2026: AVDL (2-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Below Average Performance
These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.
Number of Analysts
8 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $20.71
1 Year Target Price $20.71
| 6 | Strong Buy |
| 2 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Key Highlights
Company Size Mid-Cap Stock | Market Capitalization 2.12B USD | Price to earnings Ratio - | 1Y Target Price 20.71 |
Price to earnings Ratio - | 1Y Target Price 20.71 | ||
Volume (30-day avg) 8 | Beta 1.63 | 52 Weeks Range 6.38 - 23.57 | Updated Date 02/24/2026 |
52 Weeks Range 6.38 - 23.57 | Updated Date 02/24/2026 | ||
Dividends yield (FY) - | Basic EPS (TTM) - |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -0.11% | Operating Margin (TTM) 2.5% |
Management Effectiveness
Return on Assets (TTM) -0.34% | Return on Equity (TTM) -0.32% |
Valuation
Trailing PE - | Forward PE 16.86 | Enterprise Value 2034970832 | Price to Sales(TTM) 8.55 |
Enterprise Value 2034970832 | Price to Sales(TTM) 8.55 | ||
Enterprise Value to Revenue 8.19 | Enterprise Value to EBITDA 200.89 | Shares Outstanding 98151471 | Shares Floating 91559958 |
Shares Outstanding 98151471 | Shares Floating 91559958 | ||
Percent Insiders 1.13 | Percent Institutions 86.8 |
Upturn AI SWOT
Avadel Pharmaceuticals PLC
Company Overview
History and Background
Avadel Pharmaceuticals PLC is a biopharmaceutical company focused on developing and commercializing differentiated therapies for the treatment of central nervous system disorders. It was founded in 1990. Key milestones include the development and commercialization of several products in its history, and its current focus on narcolepsy. The company has undergone strategic shifts and product portfolio adjustments over the years to concentrate on its core therapeutic areas.
Core Business Areas
- CNS Therapeutics: Avadel is primarily focused on developing and commercializing treatments for central nervous system (CNS) disorders, with a significant emphasis on narcolepsy. Their lead product candidate addresses a significant unmet need in this area.
Leadership and Structure
Avadel Pharmaceuticals PLC is led by a management team with experience in the pharmaceutical industry. The exact structure is typical of a publicly traded biopharmaceutical company, with departments for research and development, commercial operations, finance, and regulatory affairs.
Top Products and Market Share
Key Offerings
- FTX-001 (Lumsoau2122): FTX-001, branded as Lumsoau2122, is Avadel's lead product candidate, a once-nightly formulated sodium oxybate for the treatment of excessive daytime sleepiness (EDS) and cataplexy in patients with narcolepsy. The estimated market for narcolepsy treatments is significant, with competitors including other sodium oxybate formulations and wake-promoting agents. Market share data for FTX-001 is not yet available as it is in late-stage development/awaiting approval.
Market Dynamics
Industry Overview
The biopharmaceutical industry is highly competitive and research-intensive, with a constant drive for innovation in treating unmet medical needs. The CNS disorder market, particularly narcolepsy, represents a niche but significant area with ongoing demand for improved therapies.
Positioning
Avadel Pharmaceuticals PLC is positioned as a specialized biopharmaceutical company aiming to address underserved segments within CNS disorders, particularly narcolepsy. Its strategy revolves around developing differentiated drug formulations that offer improved patient convenience and efficacy, which can be a competitive advantage.
Total Addressable Market (TAM)
The TAM for narcolepsy treatments is estimated to be in the hundreds of millions to potentially over a billion dollars annually, depending on the scope of indications and patient populations included. Avadel is positioning itself to capture a significant portion of this market with its novel, once-nightly formulation.
Upturn SWOT Analysis
Strengths
- Focused pipeline on a specific unmet medical need (narcolepsy).
- Novel formulation (FTX-001) offering potential patient convenience (once-nightly dosing).
- Experienced management team in pharmaceutical development and commercialization.
- Potential for strong intellectual property protection for its lead product.
Weaknesses
- Reliance on a single lead product candidate for significant revenue generation.
- Limited commercial history and established market presence compared to larger biopharma companies.
- Potential for regulatory hurdles and lengthy approval processes.
- Need for substantial capital investment for commercial launch and ongoing R&D.
Opportunities
- Significant unmet need in narcolepsy treatment.
- Potential for label expansion or development of other CNS therapies.
- Partnership or acquisition opportunities with larger pharmaceutical companies.
- Growing awareness and diagnosis of narcolepsy.
Threats
- Competition from existing and new narcolepsy treatments.
- Potential for pricing pressures and reimbursement challenges.
- Adverse clinical trial outcomes or regulatory setbacks.
- Changes in healthcare policy or market access.
Competitors and Market Share
Key Competitors
- Jazz Pharmaceuticals (JAZZ)
- Sumitomo Pharma Co., Ltd. (owns U.S. rights to Xyrem and Xywav)
- Avadel Pharmaceuticals PLC (AVDL)
Competitive Landscape
Avadel's competitive advantage lies in its once-nightly formulation of sodium oxybate, which offers greater convenience than existing twice-nightly options. However, they face strong competition from established players with existing market share and well-known products in the narcolepsy space. Their success hinges on demonstrating clear differentiation and patient preference for their novel dosing regimen.
Growth Trajectory and Initiatives
Historical Growth: Historically, Avadel has focused on building its pipeline and securing funding for its development programs. Growth has been in terms of R&D investment and strategic advancement of its core product candidates.
Future Projections: Future growth is heavily dependent on the successful approval and commercialization of FTX-001 (Lumsoau2122). Analyst projections will be closely tied to market penetration estimates, pricing strategies, and the competitive landscape upon launch.
Recent Initiatives: Recent initiatives include advancing FTX-001 through the regulatory approval process, building out its commercial infrastructure in anticipation of a launch, and potentially exploring other CNS therapeutic opportunities.
Summary
Avadel Pharmaceuticals PLC is a biopharmaceutical company with a strong focus on its lead product, FTX-001 (Lumsoau2122), targeting the narcolepsy market. Its key strength lies in a differentiated, once-nightly formulation offering potential patient convenience. However, the company's success is heavily reliant on regulatory approval and market adoption, facing significant competition from established players. Investors should closely monitor regulatory updates and commercial launch performance.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Company SEC Filings (10-K, 10-Q)
- Pharmaceutical Industry Market Research Reports
- Financial News and Analysis Websites
Disclaimers:
This JSON output is an AI-generated analysis and should not be considered investment advice. Financial data and market information are subject to change and may contain inaccuracies. Investors should conduct their own due diligence and consult with a qualified financial advisor before making any investment decisions.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Avadel Pharmaceuticals PLC
Exchange NASDAQ | Headquaters - | ||
IPO Launch date 1996-06-07 | CEO & Director Mr. Gregory J. Divis Jr. | ||
Sector Healthcare | Industry Drug Manufacturers - Specialty & Generic | Full time employees 188 | Website https://www.avadel.com |
Full time employees 188 | Website https://www.avadel.com | ||
Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is the LUMRYZ, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of cataplexy or excessive daytime sleepiness in patients seven years of age and older with narcolepsy. The company was formerly known as Flamel Technologies SA and changed its name to Avadel Pharmaceuticals plc in January 2017. Avadel Pharmaceuticals plc was incorporated in 2015 and is headquartered in Dublin 2, Ireland. As of February 12, 2026, Avadel Pharmaceuticals plc operates as a subsidiary of Alkermes plc.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.